Back to Search
Start Over
Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
- Source :
- Current Oncology, Vol 28, Iss 216, Pp 2346-2350 (2021), Current Oncology
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They support the use of the combination of erlotinib and bevacizumab as the first therapeutic option in this rare condition. In the present study, we report a rare case of this condition in an 18-year-old male with a family history of kidney cancer whom we successfully treated with surgery and a novel drug treatment modality based on the combination of an immune check-point inhibitor (ICPI) and a tyrosine-kinase inhibitor (TKI) with excellent and promising results.
- Subjects :
- hereditary leyomiomatosis
Oncology
medicine.medical_specialty
Bevacizumab
axitinib
030232 urology & nephrology
Case Report
Pembrolizumab
renal cell cancer
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Family history
RC254-282
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cancer
medicine.disease
Clinical trial
Axitinib
030220 oncology & carcinogenesis
pembrolizumab
Erlotinib
business
Kidney cancer
medicine.drug
Subjects
Details
- ISSN :
- 17187729
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- Current Oncology
- Accession number :
- edsair.doi.dedup.....07cf5a5d4e2736b471ece94c9733f3d2